NYMX Stock Price, Chart, Stats & News
Nymox Pharmaceutical Corporation (NYMX) does not currently pay a dividend.
NYMX chart
Price history is unavailable
We don't have enough price data for NYMX to draw a chart yet.
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 0.08% |
ROA | -404.37% |
ROE | 1330.16% |
D/E | -0.36x |
Interest coverage ratio | -154.70x |
NYMX valuation
P/E | – |
P/S | – |
P/B | -37.07x |
P/CF | -3.43x |
P/FCF | -3.51x |
P/OCF | -3.43x |
PEG | -0.03x |
EV multiple | -3.10x |
About
Nymox Pharmaceutical Corporation operates as a biopharmaceutical firm, primarily focused on the discovery and advancement of medications for the aging population across Canada, the United States, Europe, and other international regions. The company's leading experimental compound is Fexapotide Triflutate (NX-1207), which has successfully concluded Phase III clinical trials for benign prostatic hyperplasia treatment. It has also completed Phase II trials for localized low-grade prostate cancer and is currently in preclinical studies for hepatocellular carcinoma.
Similar securities
Based on sector and market capitalization
